Acute Myeloid Leukemia | Oncology Today with Dr Neil Love — Novel Agents and Strategies in AML

Featuring perspectives from Dr Daniel Pollyea, including the following topics: Introduction (0:00) Acute Myeloid Leukemia (AML), 2014 to 2022 (3:35) Defining AML versus Myelodysplastic Syndromes (6:06) Case: A man in his early 80s presenting with cytopenias and AML (8:56) Oral Decitabine/Cedazuridine (18:15) Management of Cytopenias with HMA (Hypomethylating Agent)/Venetoclax: Drug-Drug Interactions (26:43) HMA/Venetoclax for Younger Patients (39:56) Translational Biology of AML: New Agents and Treatment Strategies (44:08) Case: A man in his mid 70s with p53-mutated AML and complex karyotype (47:48) Anti-CD47 Antibody Magrolimab (51:08) Case: A woman in her early 60s with MLL-rearranged AML after receiving 7 + 3, FLAG-IDA and azacitidine/venetoclax (54:22) CME information and select publications